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Abstract
Background: Disease and treatment related events, can adversely affect the quality of life of
patients with cancer. The purpose of this study was to translate and validate a gastric cancer specific
health related quality of life questionnaire (EORTC QLQ-STO22) for Iranian patients suffering from
gastric cancer.
Methods: Forward-backward procedure was applied to translate the English language version of
the EORTC QLQ-STO22 into Persian (Iranian language). Then, the questionnaire and the EORTC
core quality of life instrument (QLQ-C30) were administered to a sample of patients with
confirmed diagnosis of gastric cancer. All patients filled in questionnaires before and after one
month of treatment. Patients were divided into two groups based on intension of treatment
(curative vs. palliative). Reliability and validity of the module was tested by internal consistency and
known group comparisons, respectively.
Results: In all, 105 patients were entered into the study. Cronbach's alpha for multi-item scales
(to test reliability) ranged from 0.54 to 0.87. The questionnaire discriminated well between
clinically distinct subgroups of patients both before and after treatment lending support to its
convergent and clinical validity.
Conclusion: Overall, the Iranian version of the EORTC QLQ-STO22 demonstrated a good
reliability and clinical validity to support its use in combination with core questionnaire in outcome
studies of gastric cancer in Iran. However, using the QLQ-STO22 in a wide range of Iranian patients
with gastric cancer should allow further confirmation for its psychometric properties.
Background
Although mortality rates due to gastric cancer had been
declining for several decades, on a worldwide scale its
incidence is still high, and it is the second leading cause of
cancer death, behind lung cancer [1,2]. Recent efforts to
improve survival include pre and post-operative chemo-
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therapy and chemo-radiotherapy. However, improve-
ments in survival with multi-modal treatment may also be
associated with increased toxic side effects. Therefore full
evaluation of new treatments of gastric cancer should be
included patient-reported outcome measures such as
health related quality of life (HRQOL) as well as assess-
ment of biomarkers, pathologic responses or survival out-
comes.
Although quality of life in patients with gastric cancer is
increasingly added as outcome measure in clinical
research, it is argued that quality of life assessments in
these patients deserve more systematic studies using gas-
tric cancer specific instruments. A recent review of the lit-
erature on quality of life in gastric cancer indicated that in
most reported studies quality of life was assessed mainly
with generic measures, and the social dimensions of qual-
ity of life were largely neglected [3]. In assessing quality of
life in cancer patients it is recommended that to use a can-
cer-specific questionnaire as a general measure of quality
of life in cancer patients (e.g. the EORTC QLQ-C30) plus
site-specific modules (e.g. breast cancer specific or gastric
cancer specific). Thus, for instance the EORTC, in addition
to core cancer quality of life questionnaire, has developed
several site-specific questionnaires including gastric spe-
cific quality of life measures (the EORTC QLQ-STO22) in
order to collect more relevant patient-reported outcomes
in studying quality of life in this group of cancer patients.
The QLQ-STO22 has been translated into many languages
such Dutch, Danish, French, German, Geek, Hungarian,
Italian, Japanese, Korea, Norwegian, Portuguese, Brazil-
ian, Russian, Spanish, Taiwanese and Turkish [4,5].
Gastric cancer is the most common cancer in Iran and
according to the latest published data there are more than
5000 new cases and equally about 5000 deaths each year
due to gastric cancer [6]. Thus as one might realize study-
ing quality of life in gastric cancer patients in Iran is very
important and relevant. Since the EORTC QLQ-STO22
was not available in Iran, this study carried out to translate
and provide evidence for its psychometric properties in
Iran so that the questionnaire could be used in the future
outcome studies in gastric cancer patients with the hope
that this might contribute to the existing literature and
help to improve quality of life among these cancer
patients.
Methods
Design and data collection
This was an observational 4-week follow up study con-
ducted in the Medical Oncology Department of the Can-
cer Research Center of the Tehran University of Medical
Science. A consecutive sample of patients were entered
into the study during March 2005 to September 2007. Eli-
gible cases were gastric cancer patients with confirmed
diagnosis and life expectancy of at least 4 weeks. Patients
were excluded if they had concurrent malignancies or if
they were unable to understand the questionnaire.
The questionnaire
Permission was asked from the EORTC Quality of Life
Department to develop the Iranian version of the EORTC
gastric cancer specific quality of life questionnaire
(EORTC QLQ-STO22). We used the standard 'forward-
backward' procedure in order to translate the English lan-
guage version of the EORTC QLQ-STO22 into Persian
(Iranian language). The translated module was reviewed,
pre-tested, revised and its final form was used in this
study. In addition the Iranian version of the EORTC QLQ-
C30 was administered to patients. The psychometric
properties of the Iranian version of the EORTC QLQ-C30
are well documented [7]. Patients completed the ques-
tionnaires before starting chemotherapy or supportive
care. The second assessment was carried out four weeks
later. At baseline assessment, patients were asked to com-
plete a short debriefing questionnaire about the time took
to complete the questionnaires, the need for help in com-
pleting the questionnaire and indicating if any of the
items appeared confusing, difficult to answer or upsetting.
Demographic and treatment data were also recorded.
The EORTC QLQ-STO22 module contains 22 items in a
similar layout and response format to the EORTC QLQ-
C30. The module consists of five multi-item scales (dys-
phagia, eating restrictions, pain, reflux, and anxiety) and
four single items (dry mouth, body image, hair loss, and
taste problem). Higher scores on the QLQ-STO22 repre-
sent greater level of symptoms [5].
Statistical analysis
Reliability: internal consistency and test-retest analyses
were performed to test reliability. The internal consistency
of the multi-item scales was assessed by Cronbach's alpha
coefficient at baseline and four week later. Values equal to
or greater than 0.7 were considered satisfactory [8]. Test-
retest reliability of the questionnaire was examined using
intraclass correlation coefficients (ICC) between pre- and
post-treatment assessments. Values of ICC vary from zero
(totally unreliable) to 1 (perfectly reliable). Values above
0.80 were considered as evidence of excellent reliability
[9].
Validity: convergent validity and clinical validity were per-
formed to examine scale validity. Convergent validity for
each scale was assessed using the correlation between each
item and its own scale corrected for overlap. It was
expected that the correlation between an item and its own
scale was significantly higher than its correlation with
other scales. Pearson's correlation coefficient was used toBMC Cancer 2009, 9:305 http://www.biomedcentral.com/1471-2407/9/305
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test convergent validity and values of 0.40 or above were
considered satisfactory (r ≥ 0.81-1.0 as excellent, 0.61-
0.80 very good, 0.41-0.60 good, 0.21-0.40 fair, and 0-0.20
poor) [8,9].
Known group comparisons was used for analysis of the
clinical validity of the Iranian version of the QLQ-STO22
in order to explore the extent to which the questionnaire
is able to discriminate between subgroups of patients.
Known groups used for this comparison were treatment
groups (potentially curative vs. palliative). Group differ-
ences were assessed using a non-parametric test (Mann-
Whitney U test).
Ethics
Ethics committee of Tehran University of Medical Sci-
ences approved the study. Written informed consent was
obtained from all enrolled patients.
Results
In total, 105 patients filled in both questionnaires the
EORTC QLQ-C30 and QLQ-STO22. Of these, 50 had
loco-regional disease and received curative therapy
(chemotherapy and surgery), while 55 had advanced dis-
ease and poor performance and received palliative treat-
ment. The mean age of patients was 58.1 years (SD =
10.7), and 76% were male (n = 72). The average time
required to complete the questionnaire was 5 minutes.
Almost all patients found the questionnaire easy to under-
stand and acceptable. However, a few patients com-
mented that they could not differentiate between 'acid
indigestion and hurt burn' (item 39) or some patients
stated that they could not understand what does 'trouble
with belching' really mean while in general belching is
unpleasant condition (item 40).
Table 1 shows the internal consistency for the five QLQ-
STO22 multi-item scales. In general all scales except eat-
ing restrictions (α = 0.54) showed satisfactory results.
Intraclass correlation coefficient (ICC) values for the Ira-
nian version of QLQ-STO22 also indicated acceptable
test-retest reliability for the questionnaire. ICC values
ranged from 0.53 for eating restrictions to 0.84 for dys-
phagia.
Item convergent validity of the QLQ-STO22 is shown in
Table 2. There were a desirable correlation between each
item and its own scale lending support to its item-compo-
nent validity. As indicated in Table 2 the correlation
between an item and its own scale was significantly higher
than its correlation with other scales.
Table 3 and Table 4 are presenting the results obtained
from known group comparisons before and after treat-
ment. In both assessments, patients in different groups
that are curative and palliative treatment groups showed
significant differences for most quality of life scores.
Discussion
This was a validation study of the EORTC QLO-STO22 in
Iran and in general the questionnaire showed promising
psychometric results. In addition patients received it well
and we did not notice any problems when it was admin-
istered to the Iranian patients reflecting the fact that the
translation was satisfactory and easy to understand.
In general the reliability of the Iranian version of the
QLQ-STO22 was relatively good. However, internal con-
sistency for two multi-item scales (reflux and eating
restrictions) was lower than recommended value. The
internal consistency for reflux subscale at baseline assess-
ment was 0.62 and for eating restrictions at both assess-
Table 1: Descriptive statistics and scale reliability of the EORTC QLQ-STO22 (n = 105)
Pre treatment Follow up
Mean (SD) Cronhbach's alpha* Mean (SD) Cronhbac's alpha*
Multi-item Scales**
Dysphagia 21.8 (25.0) 0.72 20.0 (26.3) 0.81
Stomach pain 33.1 (26.3) 0.78 30.1 (26.3) 0.87
Reflux 26.8 (23.1) 0.62 27.2 (24.5) 0.74
Eating restrictions 32.8 (14.0) 0.54 31.1 (15.2) 0.61
Anxiety 56 (31.3) 0.87 55.8 (32.8) 0.93
* A value of 0.70 or above indicates adequate reliability
** Scores range from 0 to 100 (higher scores indicate worse conditions)BMC Cancer 2009, 9:305 http://www.biomedcentral.com/1471-2407/9/305
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ments was 0.54, and 0.61 respectively. It seems that since
the internal consistency for the reflux improved in the sec-
ond assessment thus it could be regarded as satisfactory.
But it appears that the low internal consistency for the eat-
ing restrictions subscale could not be neglected. It seems
that item 42 (have you had trouble enjoying your meals?)
that belongs to this subscale needs some modification in
the future studies. Item 42 is a very straightforward ques-
tion and we did not have nor any problems in translating
the item into Persian language nor any patients indicated
difficulties in responding to this question. Yet, we are not
certain why the internal consistency for this scale was
lower than recommended value. Perhaps 'enjoyment of
meals' might mean different thing in our culture as com-
Table 2: Correlation between multi-item scales and its own scale corrected for overlap (figures are Pearson correlation coefficient 
obtained from pretreatment assessment)*
Dysphagia Pain Reflux Eating restrictions Anxiety
Dysphagia
Problems eating solid foods 0.82 0.52 0.40 0.22 0.21
Problems eating liquidized or soft food 0.87 0.34 0.29 0.01 0.08
Problems drinking liquids 0.78 0.17 0.23 0.04 0.03
Pain
Eating discomfort 0.61 0.76 0.55 0.32 0.33
Stomach pain 0.31 0.84 0.38 0.34 0.23
Stomach discomfort 0.27 0.89 0.46 0.42 0.31
Abdomen bolting 0.21 0.62 0.41 0.24 0.36
Reflux
Acid or bile problem 0.30 0.44 0.83 0.21 0.30
Acid indigestion or heartburn 0.24 0.52 0.73 0.21 0.18
Belching trouble 0.35 0.33 0.69 0.39 0.25
Eating restrictions
Full up too quickly 0.34 0.54 0.46 0.74 0.35
Trouble enjoying meals 0.38 0.34 0.20 0.72 0.08
Long time to complete meals 0.20 0.40 0.33 0.74 0.38
Eating trouble in front of other people 0.08 0.46 0.35 0.77 0.20
Anxiety
Thinking about illness 0.19 0.39 0.31 0.43 0.92
Worry about low weight 0.18 0.42 0.37 0.34 0.85
Health worry 0.04 0.28 0.01 0.07 0.46
* Similar results were obtained from the post-treatment assessment. To avoid confusion the correlation coefficients are not presented in this table.
** Excellent correlation ≥ 0.81-1.0, 0.61-0.80 very good, 0.41-0.60 good, 0.21-0.40 fair, and 0-0.20 poorBMC Cancer 2009, 9:305 http://www.biomedcentral.com/1471-2407/9/305
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Table 3: The known groups comparison before treatment
Curative treatment
(n = 50)
Palliative treatment
(n = 55)
Mean (SD) Mean (SD) P*
EORTC QLQ-C30 
Functioning scores**
Physical functioning 75.3 (15.8) 55.1 (23.5) < 0.0001
Role functioning (19.5) 77.7 60.3 (27.3) 0.001
Emotional functioning 67.1 (25.1) 53.4 (26.6) 0.008
Cognitive functioning 96.4 (10.9) 90.6 (14.7) 0.009
Social functioning 78.6 (16.7) (25.2)71.8 0.26
Global quality of life 45.7 (11.8) 39.2 (10.5) 0.007
Symptom scores***
Fatigue 36.0 (24.4) 56.8 (27.1) < 0.0001
Nausea & vomiting 10.0 (22.3) 24.2 (28.1) 0.001
Pain 30.4 (24.1) 52.8 (28.3) < 0.0001
Dyspnea 6.0 (14.5) 9.6 (20.9) 0.51
Insomnia 27.3 (33.4) 46.0 (35.4) 0.006
Appetite loss 34.0 (38.9) 54.0 (37.6) 0.007
Constipation 10.6 (24.6) 27.7 (37.6) 0.009
Diahrea 5.3 (15.5) 5.5 (16.8) 0.91
Financial difficulties 80.8 (30.0) 72.8 (36.6) 0.26
QLQ-STO22 scores***
Dysphagia 15.6 (20.6) 29.1 (28.3) 0.01
Stomach area pain 25.0 (24.4) 38.3 (24.4) 0.005
Reflux 20.3 (20.1) 30.3 (24.6) 0.03
Eating restrictions 29.9 (14.9) 33.3 (16.1) 0.44
Anxiety 50.3 (27.6) 65.3 (29.4) 0.01BMC Cancer 2009, 9:305 http://www.biomedcentral.com/1471-2407/9/305
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Dry mouth 29.2 (35.1) 52.3 (35.3) 0.001
Taste problem 20.4 (32.5) 31.2 (33.6) 0.06
Body image 20.9 (24.7) 26.6 (33.5) 0.73
Hair loss 17.3 (33.4) 18.8 (27.2) 0.51
* P values derived from Mann-Whitney test
** Scores range from 0 to 100 with higher scores indicating better conditions.
*** Scores range from 0 to 100 with higher scores indicating greater level of symptoms.
Table 3: The known groups comparison before treatment (Continued)
Table 4: The know groups comparison after treatment
Curative treatment
(n = 50)
Palliative treatment
(n = 55)
Mean (SD) Mean (SD) P*
EORTC QLQ-C30
Functioning scores**
Physical functioning 71.4 (21.8) 52.7 (23.6) < 0.0001
Role functioning 74.4 (22.6) 61.2 (27.4) 0.02
Emotional functioning 66.2 (26.1) 56.9 (25.5) 0.08
Cognitive functioning 94.4 (12.8) 89.1 (17.7) 0.07
Social functioning 79.4 (16.1) 68.9 (26.8) 0.12
Global quality of life 50.1 (18.2) 38.4 (11.9) 0.003
Symptom scores***
Fatigue 40.0 (26.1) 54.3 (29.9) 0.01
Nausea & vomiting 15.9 (19.8) 33.3 (32.7) 0.01
Pain 25.9 (22.0) 43.3 (28.0) 0.001
Dyspnea 2.8 (9.4) 12.0 (20.1) 0.009
Insomnia 29.7 (31.6) 42.7 (35.5) 0.07
Appetite loss 10.6 (24.6) 27.7 (37.6) 0.009
Constipation 10.8 (23.3) 19.1 (27.5) 0.05
Diahrea 11.5 (21.3) 15.6 (28.5) 0.63
Financial difficulties 78.0 (32.1) 77.7 (33.3) 0.89
QLQ-STO22 scores***BMC Cancer 2009, 9:305 http://www.biomedcentral.com/1471-2407/9/305
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pared to the meaning of 'enjoyment of meals' in western
countries. It is not surprising that a similar study from Tai-
wan also reported that the internal consistency of the eat-
ing restrictions subscale was lower that recommended
value (0.67) [10]. In addition, although a study from
Japan reported high internal consistency for all five multi-
item subscales including eating restrictions subscale
(ranging from 0.76 to 0.88), it was found that item 42
showed higher correlation with dysphagia scale and even
in factor analysis loaded highly on pain subscale rather
that eating restrictions subscale. As suggested there might
be a need to discuss with EORTC Quality of Life Group to
establish an agreement on the various language versions
of the QLQ-STO22 [11].
Clinical validity of the questionnaire, as examined by
using known-group comparisons, showed satisfactory
results. The questionnaire discriminated well between two
groups that differed in their clinical status receiving two
different regimens. Differences in quality of life scores on
both measures (QLQ-C30 and QLQ-STO22) between
patients who received curative treatment and those who
received palliative treatment in most instances were signif-
icant at pre- and post-treatment assessments (Table 3 and
Table 4). However, unlike most studies already cited in
this paper there were no significant differences between
two groups for social functioning. One possible explana-
tion for such observation might be related to the fact that
in Iran social ties are relatively very strong and thus both
patient groups received equal support from family, rela-
tives and friends.
The present study indicated that global quality of life was
the most adversely affected subscale among the respond-
ents while others have shown that patients scored lower
on social functioning [12]. Lower score for global quality
of life in other cancer patients were also reported. For
instance, a recent study form Kuwait (very similar in cul-
ture to our patients) reported that global quality of life in
breast cancer was lower than other functioning scores
[13]. Such similarities or dissimilarities between patients
from different cultures might worth to be studied further.
However, it seems that effective treatment could help to
improve quality of life in gastric cancer patients [14,15].
Although there was excellent patient compliance, we need
more exploration of cross-cultural differences. Further
studies with larger samples are also needed to confirm the
sensitivity to changes over time.
Conclusion
Overall the Iranian version of the EORTC QLQ-STO22
showed that it is a reliable and valid specific measure of
quality of life in patients with gastric cancer. However,
using the QLQ-STO22 in a wide range of Iranian patients
with gastric cancer should allow further confirmation for
its psychometric properties.
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